Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

  • Martin Bidlingmaier, Endocrine Laboratory, Ludwig Maximilian University of Munich
  • ,
  • Beverly M.K. Biller, Harvard University
  • ,
  • David Clemmons, University of North Carolina
  • ,
  • Jens Otto L. Jørgensen
  • Hiroshi Nishioka, Toranomon Hospital
  • ,
  • Yutaka Takahashi, Nara Medical University, Graduate School of Medicine

Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life. Daily subcutaneous injections with recombinant growth hormone (GH) can alleviate the abnormalities associated with AGHD. Several long-acting GH (LAGH) preparations are currently in development that aim to reduce treatment burden for patients receiving daily GH injections. Somapacitan (Sogroya®; Novo Nordisk, Denmark) is the first LAGH preparation that has been approved for treatment of AGHD in the United States, Europe, and Japan. The recent approval of somapacitan and anticipated approval of other LAGH molecules presents new questions for physicians planning to treat AGHD with LAGH in the future. Differences in the technologies used to prolong the half-life of recombinant GH are expected to result in variations in pharmacokinetic and pharmacodynamic profiles between preparations. Therefore, it is essential that physicians understand and consider such variations when treating patients with these novel GH replacement therapies. Here, we present a set of treatment recommendations that have been created to guide physicians initiating therapy with somapacitan in patients with AGHD who are eligible for GH replacement. Furthermore, we will review the published data that underlie these recommendations to explain the rationale for the treatment and monitoring advice provided.

Original languageEnglish
Article number1040046
JournalFrontiers in Endocrinology
Publication statusPublished - Dec 2022

Bibliographical note

Publisher Copyright:
Copyright © 2022 Bidlingmaier, Biller, Clemmons, Jørgensen, Nishioka and Takahashi.

    Research areas

  • adult growth hormone deficiency, growth hormone, insulin-like growth factor I, long-acting growth hormone, pharmacokinetic/pharmacodynamic modelling, somapacitan, treatment recommendations

See relations at Aarhus University Citationformats

ID: 302836733